Stories about Molecule

Subscribe to topic

Subscribe to Molecule

16.01.2020 – 12:51
Technische Universität München
Self-assembled complex porous, chiral nano-patterns arise from a simple linear building block
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/35868/ High resolution images: https://mediatum.ub.tum.de/1535044 NEWS RELEASE Pretty with a twist Complex porous, chiral nano-patterns arise from a simple ...
more
10.01.2020 – 12:00
Jennewein Biotechnologie GmbH
Jennewein Biotechnologie GmbH enforces its patents in the field of human milk oligosaccharides against Nestlé in Germany
Rheinbreitbach (ots) - Jennewein Biotechnologie GmbH filed a patent infringement suit with the regional court in Mannheim on January 09, 2020 against Nestlé Nutrition GmbH and its holding company Nestlé Deutschland AG. Nestlé offers its infant formula Beba Supreme which contains two human milk oligosaccharides - ...
more
09.01.2020 – 09:03
Technische Universität München
Gene network helps to turn white fat into beneficial calorie burning fat
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/about-tum/news/ High resolution images: https://mediatum.ub.tum.de/1524726 NEWS RELEASE A new approach to treating overweight and obesity Gene network helps to turn white fat into beneficial calorie ...
more
08.01.2020 – 17:00
Jennewein Biotechnologie GmbH
Publication of a toxicological study: a milestone for Jennewein Biotechnologie for the GRAS approval of the HMO-mix
Rheinbreitbach (ots) - Jennewein Biotechnology announces another milestone in the Worldwide approval of a new product generation, the "HMO-Mix". The data of the toxicological study, with the title "A Safety Evaluation of Mixed Human Milk Oligosaccharides in Rats", was recently accepted for publication by the ...
more
16.12.2019 – 17:07
Technische Universität München
From cancer medication to antibiotic: modified cancer drug effective against multi-resistant bacteria
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/35822/ High resolution images: https://mediatum.ub.tum.de/1524870 NEWS RELEASE From cancer medication ...
more
25.11.2019 – 10:13
Jennewein Biotechnologie GmbH
Jennewein Biotechnologie obtains US-FDA GRAS status on alternative 2'-fucosyllactose fermentation strain
Rheinbreitbach (ots) - Jennewein Biotechnologie GmbH, Rheinbreitbach, the leading manufacturer of human milk oligosaccharides (HMOs), announces that the U.S. Food and Drug Administration (FDA) issued a "no question" response letter to Jennewein's supplement of its GRAS Notice GRN571, thereby acknowledging that the ...
more
25.11.2019 – 10:02
Jennewein Biotechnologie GmbH
Jennewein Biotechnologie sues Glycom for patent infringement in Denmark
Rheinbreitbach (ots) - Jennewein Biotechnologie develops fermentative processes for manufacturing of human milk oligosaccharides (HMOs) cost efficiently in an industrial scale since 2005 to make these special sugars available for affordably priced infant formula and other uses in food. Jennewein Biotechnologie was the first commercial vendor of HMOs, and brought the ...
more
14.11.2019 – 14:33
Technische Universität München
Anticipating silicon solar cells with significantly improved efficiency: new synthesis approach for soluble silicon clusters
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/35779/ High resolution images: https://mediatum.ub.tum.de/1523937 NEWS RELEASE Anticipating silicon ...
more
08.11.2019 – 09:00
Debiopharm International SA
Debiopharm progresses in their stand against drug-resistant N. gonorrhoeae with extended CARB-X funding of their Debio 1453 antibiotic program
Lausanne (ots) - Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today it has been awarded the 2nd phase funding from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to continue the development of its antibiotic program Debio 1453, leading to a novel ...
more
28.10.2019 – 10:27
Fraunhofer Institut für Angewandte Festkörperphysik IAF
3
World's first production of aluminum scandium nitride via MOCVD
more
25.10.2019 – 10:03
Helmholtz Zentrum München
Helmholtz Zentrum München allies with Eli Lilly and Company to discover new targets for pancreatic beta cell regeneration in the treatment of diabetes
more
17.10.2019 – 17:34
Fördergesellschaft IZB mbH
The development of a combination drug for immunotherapy and trends of the VC and pharmaceutical branch were introduced at the IZB
more
One document
17.10.2019 – 16:55
Versameb AG
Versameb raises CHF 6.4 million in Seed C round and strengthens the team
Basel (ots) - Versameb AG, a Swiss biopharmaceutical company, announced today the successful closing of a CHF 6.4 million Seed C financing round, bringing the total capital raised to date to CHF 11.8 million. Versameb is focusing on the discovery and development of innovative, next-generation RNA-based drugs. The proceeds of this financing round will be used to expand ...
more
17.10.2019 – 11:13
Technische Universität München
How roots grow hair: "Smoke detectors" in plants also control the growth of root hair
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/35739/ High resolution images: https://mediatum.ub.tum.de/1521816 NEWS RELEASE How roots grow hair "Smoke detectors" in plants also control the growth of ...
more
10.10.2019 – 09:38
UCB Pharma
UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases
Brussels and Cambridge, Massachusetts (ots/PRNewswire) - - Will enhance UCB's leadership potential in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside to UCB's rozanolixizumab, an FcRn targeting antibody also in phase 3 - ...
more
27.09.2019 – 12:00
Sysmex Inostics GmbH
Sysmex Inostics launches two NGS-based liquid biopsy panels for cancer therapy drug development
Hamburg, Germany and Baltimore, Maryland (ots) - Sysmex Inostics announces the availability of the SafeSEQ Breast Cancer and Head and Neck Cancer Panels along with the SafeSEQ Rapid Custom Development program for circulating tumor DNA (ctDNA) analysis. SafeSEQ is a next-generation sequencing (NGS)-based approach that delivers sensitivity comparable to the clinically ...
more
16.09.2019 – 11:07
Brenntag AG
Brenntag Specialties, Inc., expands distribution agreement with BASF
Dear all, Please find attached Brenntag's press release regarding Brenntag Specialties, Inc., becoming the exclusive distributor for BASF's amine curing agents in the Western and Southwestern United States, effective October 15, 2019.. For further information please see the press release. Please do not hesitate to contact us if you have further questions. Best ...
more
11.09.2019 – 17:00
Jennewein Biotechnologie GmbH
Administrative Law Judge issues ruling in patent dispute concerning 2'-FL production and beta-galactosidase activity
Rheinbreitbach (ots) - On September 09, 2019, Administrative Law Judge Cameron Elliot of the US International Trade Commission issued an Initial Determination finding that one of the bacterial strains used by Jennewein Biotechnologie to make 2'-fucosyllactose (2'-FL) infringes a patent owned by Glycosyn LLC. In the ...
more
10.09.2019 – 09:40
Grünenthal Group
Grünenthal and Mesoblast Enter Strategic Partnership for Europe and Latin America to Develop and Commercialise Innovative Cell Therapy for the Treatment of Chronic Low Back Pain
Aachen, Germany, and Melbourne, Australia (ots) - Grünenthal, a global leader in pain management, and Mesoblast Limited (ASX: MSB; Nasdaq: MESO), a world leader in allogeneic cellular medicines for inflammatory diseases, today announced that they have entered into a strategic partnership to develop and ...
more
04.09.2019 – 12:00
Sysmex Inostics GmbH
Sysmex Inostics publishes first feasibility study of NGS-based liquid biopsy to complement early breast cancer screening by imaging
Hamburg/Baltimore (ots) - Using Sysmex Inostics' novel SafeSEQ next-generation sequencing cell-free DNA technology, investigators from the Biomedical Research Institute of Malaga [(IBIMA)-CIMES-UMA, Malaga Spain] and collaborators have published the first pilot study to examine the use of a non-invasive liquid ...
more
13.08.2019 – 14:15
Helmholtz Zentrum München
BART-Seq: A Novel Method to Characterize Genes with High-Precision in Single Cells
The analysis of gene products in cells is an important tool for diagnosing disease and the design of new active substances in biological and medical research. At Helmholtz Zentrum München, a method of targeted RNA sequencing (transcriptome analysis) has now been developed, which precisely detects the smallest amounts of gene transcripts in single cells. The method ...
more
30.07.2019 – 11:50
Technische Universität München
Better food quality control: Food profilers develop new methodological approach for food analysis
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: http://www.tum.de/nc/en/about-tum/news/press-releases/details/35607/ High resolution images: https://mediatum.ub.tum.de/1515306 NEWS RELEASE Better food quality ...
more
30.07.2019 – 10:50
Technische Universität München
Better food quality control: Food profilers develop new methodological approach for food analysis
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: http://www.tum.de/nc/en/about-tum/news/press-releases/details/35607/ High resolution images: https://mediatum.ub.tum.de/1515306 NEWS RELEASE Better food quality ...
more
17.07.2019 – 17:08
Technische Universität München
The physiology of survival: for bacteria, the neighbors co-determine which cell dies first
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/35582/ High resolution images: https://mediatum.ub.tum.de/1513622 NEWS RELEASE The physiology of survival For bacteria, the neighbors co-determine which ...
more
12.07.2019 – 17:04
Fördergesellschaft IZB mbH
High investor density at the Pitch Day hosted by IZB
more
One document
24.06.2019 – 10:52
Fraunhofer Institut für Angewandte Festkörperphysik IAF
3
Fingerprint spectroscopy within a millisecond
more
03.06.2019 – 09:00
Debiopharm International SA
Caris Life Sciences Partners with Debiopharm International SA to Develop Companion Diagnostic for Detection of Rare FGFR Fusions Using Novel Molecular Intelligence (MI) Transcriptome(TM)
Irving, Texas (ots) - Caris to develop CDx for Debiopharm's FUZE Phase II Pivotal Trial of Debio 1347 in solid tumor patients with FGFR fusions Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced that it has entered into a strategic ...
more

123Next